Project Grant R21DK142595
Award Date 9/19/25
Completion Date 9/18/27
Dollars Obligated $430K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Georgia, USA
Similar Awards
- This $1,554,672 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) supports research to define the molecular mechanisms of gut inflammation and barrier dysfunction in people with HIV. The research aims to investigate how HIV-infected immune cells impact intestinal epithelial integrity, with a focus on the role of the CARD8 inflammasome. The grantee, Washington University, will...
- This $1,778,953 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) will support research to investigate the relationship between HIV persistence, chronic immune activation, and metabolic complications in people living with HIV. The primary objectives are to explore the natural history of metabolic dysfunction in the context of persistent HIV reservoirs and chronic inflammation,...
- This Project Grant award of $653,693.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to Emory University is supporting structural analyses of the HIV-1 virion using cryo-electron microscopy and related techniques. The research aims to gain a detailed understanding of the molecular mechanisms involved in HIV-1 assembly, maturation, and entry into host cells. This work is expected to inform the development and...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $617,376 to Emory University to conduct research on the activation and maturation of the HIV-1 virus. The key objectives are to: 1) Measure the timing of protease (PR) activation relative to HIV-1 budding from the host cell, 2) Assess the rate and extent of PR substrate cleavage and correlate this with formation of...
- This $238,972 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports research to determine the mechanism by which the cellular protein EHD4 decreases the infectivity of HIV-1 virions. The research plan aims to 1) characterize how EHD4 blocks the incorporation of HIV-1 envelope glycoproteins into virions, 2) investigate the antiviral role of EHD4 within virions, and 3) elucidate the impact of the HIV-1...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Federal Grant Program for Cardiovascular Diseases Research (CFDA 93.837), provides $123,104 to Emory University to conduct research on factors contributing to cardiovascular disease (CVD) comorbidities in persons living with HIV (PWH). The key objectives are to: 1) assess relationships between the metabolome, lipidome, HIV reservoir, and subclinical CVD, analyzing differences by sex; and 2) determine...
- This $197,366.00 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to advance the understanding of how the human immune system naturally restricts a specific subset of HIV, known as X4-tropic virus. The key objectives are to: (1) characterize the molecular mechanisms driving the restriction of X4-tropic viral replication in the presence of R5-tropic virus, and (2) understand the mechanism underlying...
- This federal Project Grant award, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to investigate the impact of a glucagon-like peptide-1 receptor agonist on pathogenesis and antiretroviral therapy (ART) administration in people living with HIV (PWH). The $780,853 award, with a period of performance from April 10, 2025 to March 31, 2030, will support research...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) provides $223,300 to Emory University to develop novel HIV capsid-targeting antivirals that can maintain activity against viruses resistant to the recently approved drug lenacapavir. The research aims to identify compounds that can bind the HIV capsid protein even in the presence of mutations that confer resistance to lenacapavir. This work includes...
- The federal Project Grant award of $400,125 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research by Meharry Medical College to elucidate a novel mechanism by which HIV-1 evades the antiviral function of the APOBEC3G (A3G) protein. The research aims to 1) compare A3G-related mutation profiles in infected cells and viral particles, focusing on key RNA packaging elements, and 2) investigate the impact of these...